These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 32194860

  • 1. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
    Chen J, Ge X, Zhang W, Ding P, Du Y, Wang Q, Li L, Fang L, Sun Y, Zhang P, Zhou Y, Zhang L, Lv X, Li L, Zhang X, Zhang Q, Xue K, Gu H, Lei Q, Wong J, Hu W.
    Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
    [Abstract] [Full Text] [Related]

  • 2. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma.
    Liu YY, Leboeuf C, Shi JY, Li JM, Wang L, Shen Y, Garcia JF, Shen ZX, Chen Z, Janin A, Chen SJ, Zhao WL.
    Blood; 2007 Jul 01; 110(1):339-44. PubMed ID: 17379744
    [Abstract] [Full Text] [Related]

  • 3. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
    Bouwstra R, He Y, de Boer J, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Zu Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T.
    Cancer Immunol Res; 2019 Oct 01; 7(10):1663-1671. PubMed ID: 31409608
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM.
    Clin Cancer Res; 2000 Dec 01; 6(12):4950-6. PubMed ID: 11156256
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM.
    Ann Hematol; 2013 Oct 01; 92(10):1351-8. PubMed ID: 23636313
    [Abstract] [Full Text] [Related]

  • 13. Tissue microarray in a subset of South African patients with DLBCL.
    Sissolak G, Wood L, Smith L, Chan JW, Armitage J, Jacobs P.
    Transfus Apher Sci; 2013 Oct 01; 49(2):120-32. PubMed ID: 23942329
    [Abstract] [Full Text] [Related]

  • 14. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
    Wang S, Sun L.
    Bioengineered; 2021 Dec 01; 12(1):8296-8308. PubMed ID: 34565287
    [Abstract] [Full Text] [Related]

  • 15. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
    Chen J, Xu-Monette ZY, Deng L, Shen Q, Manyam GC, Martinez-Lopez A, Zhang L, Montes-Moreno S, Visco C, Tzankov A, Yin L, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Pham L, Young KH.
    Oncotarget; 2015 Mar 20; 6(8):5597-614. PubMed ID: 25704881
    [Abstract] [Full Text] [Related]

  • 16. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.
    Blood; 2017 Jul 20; 130(3):310-322. PubMed ID: 28202458
    [Abstract] [Full Text] [Related]

  • 17. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, German High-Grade Lymphoma Study Group.
    J Clin Oncol; 2017 Aug 01; 35(22):2515-2526. PubMed ID: 28525305
    [Abstract] [Full Text] [Related]

  • 18. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S.
    Clin Cancer Res; 2012 May 01; 18(9):2534-44. PubMed ID: 22338016
    [Abstract] [Full Text] [Related]

  • 19. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH.
    Blood; 2016 Dec 29; 128(26):3083-3100. PubMed ID: 27760757
    [Abstract] [Full Text] [Related]

  • 20. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW, Langendonk M, Reitsma B, Nijland M, van den Berg A, Ammatuna E, Visser L, van Meerten T.
    Int J Mol Sci; 2019 Nov 30; 20(23):. PubMed ID: 31801186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.